- Home
- ETSS vs FENC Comparison
ETSS vs FENC Comparison
Compare ETSS & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$11.57
Company Overview
Basic Information| Metric | ETSS | FENC |
|---|---|---|
| Founded | N/A | 1996 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.6M | 230.8M |
| IPO Year | 2026 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ETSS | FENC |
|---|---|---|
| Price | $9.87 | $11.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 7.5K | ★ 127.4K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | ★ N/A | $1,084.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.87 | $5.65 |
| 52 Week High | $9.95 | $11.31 |
Technical Indicators
Market Signals| Indicator | ETSS | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 60.06 |
| Support Level | N/A | $9.91 |
| Resistance Level | $9.95 | $11.28 |
| Average True Range (ATR) | 0.02 | 0.60 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 92.92 |
Price Performance
Historical Comparison ETSS
FENC
About ETSS Energy Transition Special Opportunities Class A Ordinary Shares
Energy Transition Special Opportunities is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.